Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Neoadjuvant anastrozole versus tamoxifen in patients receiving goserelin for premenopausal breast cancer (STAGE): a double-blind, randomised phase 3 trial.

Neoadjuvant anastrozole versus tamoxifen in patients receiving goserelin for premenopausal breast... http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png The Lancet Oncology Pubmed

Neoadjuvant anastrozole versus tamoxifen in patients receiving goserelin for premenopausal breast cancer (STAGE): a double-blind, randomised phase 3 trial.

Loading next page...
 
/lp/pubmed/neoadjuvant-anastrozole-versus-tamoxifen-in-patients-receiving-BgKaWQIRtL

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

ISSN
1470-2045
DOI
10.1016/S1470-2045(11)70373-4
pmid
22265697

Abstract

Journal

The Lancet OncologyPubmed

Published: Jun 22, 2012

There are no references for this article.